OXiGENE Release: Distinguished Oncology Researcher, Dr. Robert Kerbel, Discusses The Therapeutic Potential Of Pairing Vascular Disrupting Agents With Anti-Angiogenic Drugs In The Fight Against Cancer At AACR Conference

OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer and certain ophthalmologic diseases, announced today that renowned oncology researcher, Professor Robert Kerbel, Ph.D., discussed the potential anti-tumor effects that could be achieved from combining vascular disrupting and anti-angiogenic agents as an acute combination therapy for the treatment of advanced cancers at an American Association for Cancer Research conference. Professor Kerbel discussed preliminary, preclinical results of such an approach during a session he moderated today, called “Role Of Sequencing In Anti-Angiogenic Therapy,” at the American Association for Cancer Research’s Anti-Angiogenesis and Drug Delivery to Tumors Conference: Bench to Bedside and Back, held in Waltham, Massachusetts

MORE ON THIS TOPIC